MIRA Pharmaceuticals, Inc. Common Stock (MIRA) - Total Liabilities
Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has total liabilities worth $83.93K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore MIRA Pharmaceuticals, Inc. Common Stock equity growth rate to track the company's year-over-year net asset growth rate.
MIRA Pharmaceuticals, Inc. Common Stock - Total Liabilities Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Itama Ranoraya
JK:IRRA
|
Indonesia | Rp2.16 Trillion |
|
Tongyang Pile Inc
KQ:228340
|
Korea | ₩5.49 Billion |
|
Mabion S.A.
WAR:MAB
|
Poland | zł70.76 Million |
|
Creative Realities Inc
NASDAQ:CREX
|
USA | $97.11 Million |
|
Avante Logixx Inc
V:XX
|
Canada | CA$10.84 Million |
|
Symphony Life Bhd
KLSE:1538
|
Malaysia | RM195.26 Million |
|
Compal Broadband Networks Inc
TW:6674
|
Taiwan | NT$359.37 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down MIRA Pharmaceuticals, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see MIRA Pharmaceuticals, Inc. Common Stock (MIRA) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 90.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.01 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MIRA Pharmaceuticals, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MIRA Pharmaceuticals, Inc. Common Stock (2020–2024)
The table below shows the annual total liabilities of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $723.35K | +29.61% |
| 2023-12-31 | $558.10K | -61.62% |
| 2022-12-31 | $1.45 Million | +32.96% |
| 2021-12-31 | $1.09 Million | +1110.44% |
| 2020-12-31 | $90.36K | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more